"Oncolytic Virotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.
Descriptor ID |
D050130
|
MeSH Number(s) |
E02.095.601
|
Concept/Terms |
Oncolytic Virotherapy- Oncolytic Virotherapy
- Oncolytic Virotherapies
- Virotherapies, Oncolytic
- Virotherapy, Oncolytic
- Oncolytic Virus Therapy
- Oncolytic Virus Therapies
- Therapies, Oncolytic Virus
- Therapy, Oncolytic Virus
- Virus Therapies, Oncolytic
- Virus Therapy, Oncolytic
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Virotherapy".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Virotherapy".
This graph shows the total number of publications written about "Oncolytic Virotherapy" by people in this website by year, and whether "Oncolytic Virotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 1 | 2 |
2006 | 5 | 1 | 6 |
2007 | 5 | 1 | 6 |
2008 | 7 | 3 | 10 |
2009 | 4 | 1 | 5 |
2010 | 4 | 1 | 5 |
2011 | 1 | 0 | 1 |
2012 | 3 | 1 | 4 |
2013 | 2 | 1 | 3 |
2014 | 4 | 3 | 7 |
2015 | 3 | 2 | 5 |
2016 | 5 | 2 | 7 |
2017 | 10 | 1 | 11 |
2018 | 3 | 0 | 3 |
2019 | 4 | 0 | 4 |
2020 | 6 | 1 | 7 |
2021 | 9 | 2 | 11 |
2022 | 7 | 0 | 7 |
2023 | 5 | 0 | 5 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Virotherapy" by people in Profiles.
-
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing. J Immunother Cancer. 2024 Jun 17; 12(6).
-
Oncolytic adenoviruses and immunopeptidomics: a?convenient marriage. Mol Oncol. 2024 Apr; 18(4):781-784.
-
Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther. 2024 Mar 06; 32(3):722-733.
-
Promises of oncolytic viral therapy for adult and children with brain glioma. Curr Opin Oncol. 2023 11 01; 35(6):529-535.
-
A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1531-1540.
-
Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
-
Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models. J Transl Med. 2023 07 06; 21(1):444.
-
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2023 Jun; 29(6):1370-1378.
-
Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success. Int Rev Cell Mol Biol. 2023; 379:169-188.
-
Oncolytic virotherapy for the treatment of pediatric brainstem gliomas. Rev Neurol (Paris). 2023 Jun; 179(5):475-480.